Breaking News

Tweet TWEET

Evotec AG: Fiscal Year 2012 Results Presentation on 26 March 2013 Live on the Internet

Evotec AG: Fiscal Year 2012 Results Presentation on 26 March 2013 Live on the
Internet

HAMBURG, Germany, March 19, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) is going to broadcast its press & analyst conference in Frankfurt
live on the internet. The Management Board will inform you about the FY 2012
results as well as about the status of the discovery alliance business and the
partnerships of the development projects. Moreover, they will provide the
status of "Action Plan 2016 – Innovation Efficiency" and present an outlook
for fiscal year 2013. The conference will be held in English.

Webcast details:

Date: Tuesday, 26 March 2013
Time: 09.00 am CET (08.00 am GMT/04.00 am EDT)

To join the audio webcast and to access the presentation slides you will find
a link on our home page www.evotec.com shortly before the event.

For those who prefer to listen to the presentation via phone, please dial:

From Germany: +49 (0)69 20 17 44 210
From UK:      +44 207 153 9154
From USA:    +1 877 423 0830
Access Code:  638618#

The on-demand version of the webcast will be available on our website:
www.evotec.com >Investors> Events> Financial Calendar.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech,
MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has
existing development partnerships and product candidates both in clinical and
preclinical development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes and with Roche in the
field of Alzheimer's disease. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT:  Evotec AG:
          Gabriele Hansen, Head of Corporate Communications
          Phone: +49.(0)40.56081-255
          gabriele.hansen@evotec.com